ICH – Page 133 – Pharma.Tips

High Visual Inspection Reject Rate post-sterile filtration: facility, people, process root cause mapping

Investigating High Visual Inspection Reject Rates Following Sterile Filtration High visual inspection reject rates post-sterile filtration can significantly disrupt pharmaceutical operations, leading to increased costs, delays, and potential regulatory scrutiny.…

Endotoxin Oos during terminal sterilization: risk assessment for patient safety and recall

Investigating Endotoxin OOS during Terminal Sterilization: A Risk Assessment Approach Incidents of out-of-specification (OOS) results for endotoxin levels during terminal sterilization present significant challenges in pharmaceutical manufacturing, particularly for parenteral…

Ph Drift during homogenization: packaging compatibility and stability justification

Investigating pH Drift during Homogenization: Ensuring Packaging Compatibility and Stability Pharmaceutical manufacturing processes must adhere to stringent quality standards, especially in the preparation of topical and dermatological formulations where pH…

High Visual Inspection Reject Rate during aseptic filling: CAPA package with evidence and effectiveness checks

Investigating High Visual Inspection Reject Rates during Aseptic Filling in Pharmaceutical Manufacturing High visual inspection reject rates during aseptic filling pose significant challenges for pharmaceutical manufacturers, potentially leading to product…

Sterility Test Failure during power interruption: CAPA package with evidence and effectiveness checks

Sterility Testing Failures Following Power Interruptions: An Investigation Guide Power interruptions can dramatically impact sterility testing results, leading to potential product recalls, regulatory scrutiny, and reputational damage. This article will…

Tube Leakage Complaint at accelerated stability: complaint trending and risk-based actions

Investigation of Tube Leakage Complaints During Accelerated Stability Testing In pharmaceutical manufacturing, tube leakage complaints during accelerated stability testing present critical issues, possibly leading to quality defects and regulatory concerns.…

Endotoxin Oos during hold-time study: facility, people, process root cause mapping

Root Cause Analysis of Endotoxin OOS in Hold-Time Studies: A Practical Guide In the pharmaceutical manufacturing environment, Out of Specification (OOS) results can have significant implications, especially regarding endotoxin levels…

Bioburden Spike Pre-Filtration during terminal sterilization: facility, people, process root cause mapping

Identifying and Addressing Bioburden Spikes Pre-Filtration during Terminal Sterilization in Pharmaceutical Manufacturing In the pharmaceutical manufacturing industry, the integrity of terminal sterilization processes is crucial, especially regarding parenteral dosage forms.…

Emulsion Inversion during inspection preparation: how to document deviations for FDA/EMA

Managing Emulsion Inversion during Inspection Preparation: A Compliance Investigation Guide In the realm of pharmaceutical manufacturing, ensuring the integrity of your formulations is critical, especially in the context of emulsion…

Unplanned Line Stoppage during hold-time study: risk assessment for patient safety and recall

Risk Assessment for Patient Safety Following Unplanned Line Stoppage during a Hold-Time Study In pharmaceutical manufacturing, an unplanned line stoppage during a hold-time study can pose significant risks to product…

Aseptic Gowning Deviation after maintenance intervention: risk assessment for patient safety and recall

Aseptic Gowning Deviation Investigation Post-Maintenance Intervention: Ensuring Compliance and Patient Safety Aseptic processing is pivotal in pharmaceutical manufacturing, particularly for parenteral dosage forms. When deviations occur—such as an aseptic gowning…

Odor Change during method transfer: mixing and sampling controls for QA review

Investigating Odor Changes during Method Transfers: Effective Controls for Quality Assurance Review Odor changes during method transfers can signal underlying issues that compromise product quality and regulatory compliance. This article…